The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | A “chemo-sparing” MRD-driven strategy for CLL
This is an exciting time for chronic lymphocytic leukemia (CLL) research, with the possibility of chemotherapy-free treatment approaches. In this interview, Florence Cymbalista, MD, of Avicenne Hospital, Bobigny, France, discusses the Phase II study of obinutuzumab plus ibrutinib, followed by a “chemo-sparing” strategy, in treatment-naïve CLL patients (ICLL07GAI; NCT02666898). The preliminary results are encouraging, with the full dataset highlight anticipated at next year’s meeting. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
